We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current ABCL market cap is 825.06M. The company's latest EPS is USD -0.4968 and P/E is -5.72.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
| Total Revenue | 6.6M | 9.18M | 9.95M | 7.32M | 6.51M |
| Operating Income | -54.89M | -66.05M | -54.89M | -93.45M | -93.66M |
| Net Income | -28.61M | -47.15M | -40.61M | -36.93M | -51.11M |
| Year End 31 December 2023 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 233.16M | 375.2M | 485.42M | 38.03M |
| Operating Income | 183.17M | 249.93M | 282.95M | -237.21M |
| Net Income | 118.92M | 153.46M | 158.52M | -146.4M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
| Total Assets | 1.51B | 1.49B | 1.46B | 1.41B | 1.49B |
| Total Liabilities | 329.42M | 335.78M | 333.18M | 301.51M | 335.78M |
| Total Equity | 1.18B | 1.15B | 1.13B | 1.11B | 1.15B |
| Year End 31 December 2023 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.01B | 1.32B | 1.54B | 1.49B |
| Total Liabilities | 175.03M | 292.84M | 307.63M | 335.78M |
| Total Equity | 830.51M | 1.03B | 1.23B | 1.15B |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
| Operating | -24.27M | -43.88M | -41.71M | -71.67M | -100.56M |
| Investing | -196.79M | -221.11M | 29.91M | 82.01M | 85.71M |
| Financing | 6.59M | 10.36M | 2.83M | 5.48M | 8.63M |
| Year End 31 December 2023 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 22.69M | 244.58M | 277.36M | -43.88M |
| Investing | -119.78M | -332.25M | -352.63M | -221.11M |
| Financing | 683.65M | -3.89M | -1.63M | 10.36M |
| Market Cap | 825.06M |
| Price to Earnings Ratio | -5.72 |
| Price to Sales Ratio | 22.02 |
| Price to Cash Ratio | 6.28 |
| Price to Book Ratio | 0.73 |
| Dividend Yield | - |
| Shares Outstanding | 294.67M |
| Average Volume (1 week) | 3.03M |
| Average Volume (1 Month) | 2.6M |
| 52 Week Change | -50.27% |
| 52 Week High | 6.055 |
| 52 Week Low | 2.335 |
| Spread (Intraday) | 0.07 (2.46%) |
| Company Name | AbCellera Biologics Inc |
| Address |
2215 yukon street vancouver, british columbia V5Y 0A1 |
| Website | https://www.abcellera.com |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
